Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma

29 Apr 2021

Abstract excerpt

Medulloblastoma is the most common malignant childhood brain tumor, and 5-year overall survival rates are as low as 40% depending on molecular subtype, with new therapies critically important. As radiotherapy and chemotherapy act through the induction of DNA damage, the sensitization of cancer cells through the inhibition of DNA damage repair pathways is a potential therapeutic strategy. The poly-(ADP-ribose)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33996894
DOI: 10.3389/fmolb.2021.633344

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of MedulloblastomaPMID 33996894Read ↗

PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiationSemantic proximity Read ↗

Therapeutic Application of PARP Inhibitors in Neuro-Oncology.Semantic proximity Read ↗

The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.Semantic proximity Read ↗

MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastomaSemantic proximity Read ↗

Delineation of <i>MGMT</i> Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaSemantic proximity Read ↗

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaSemantic proximity Read ↗

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.Semantic proximity Read ↗

Profile of veliparib and its potential in the treatment of solid tumorsSemantic proximity Read ↗

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastomaSemantic proximity Read ↗

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumorsSemantic proximity Read ↗

Rad51 Degradation: Role in Oncolytic Virus—Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in GlioblastomaSemantic proximity Read ↗

Olaparib: A Chemosensitizer for the Treatment of GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.